Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,deferredLongTermLiab,shortTermInvestments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,INRLF,42646000.0,99777600,,,-57661000,,-58697000,15596000,-46846000,-55011000,-55011000,-7431000,-11291000,,,,1036000,24287000,79298000,71133000,-2650000,,-58697000,-58697000,34424000.0,328688000.0,668037000.0,77070000.0,375247000.0,745107000.0,14986000.0,88525000.0,-329422000.0,109802000.0,62818000.0,23654000.0,329766000.0,456917000.0,5591000.0,7079000.0,63507000.0,123028000.0,561962000.0,2039000.0,18007000.0,47402000.0,125664000.0,71502000.0,,,267991000.0,-23045000.0,-2407000.0,80293000.0,-73083000.0,83023000.0,93853000.0,-82000.0,36688000.0,6101000.0,13000.0,-97006000.0,-13271000.0,-323000.0,4653000.0,-22840000.0,,105045000.0,en-US,US,EQUITY,False,Delayed Quote,-10.391567,23.4555 - 24.8,26.56,finmb_4550716,Other OTC,Valneva SE,EUR,3203,15400,19.3,4.288889,4.5 - 28.25,-4.450001,-0.15752216,4.5,28.25,USD,PRE,23.8,1630526275,-2.7600002,24.56,24.8,23.4555,16052,us_market,2,0,0.7023085,VALNEVA SE,PNK,-1.306,0.567,14.846857,8.953142,0.6030328,13.981014,9.818985,2397612032,41.97531,15,America/New_York,EDT,-14400000,False,False,0.71,,,28.25,4.5,14.85,13.98,3.2k,15.4k,99.78M,,71.25M,15.59%,30.92%,,,,,,,,,,,0.00%,,,1108:1000,"Jan 14, 2015","Dec 30, 2020","Jun 29, 2021",-113.86%,-108.57%,-13.15%,-133.05%,109.92M,1.19,91.40%,-28.43M,-115.38M,-125.15M,-1.31,,329.77M,3.31,111.49M,144.65,1.23,0.57,108.77M,61.59M,Value,44800,Healthcare,700,10,10,"Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",Saint-Herblain,33 2 28 07 37 10,6,1609372800,1625097600,8,France,http://valneva.com,86400,10,6 rue Alain Bombard,Biotechnology
t-1,INRLF,17199000.0,99777600,,,-28070000,,-27702000,14951000,-19167000,-31139000,-31139000,-2979000,-4607000,,,,-368000,23215000,54354000,42382000,3069000,,-27702000,-27702000,35156000.0,247074000.0,521757000.0,52355000.0,239152000.0,574112000.0,13765000.0,58568000.0,-261251000.0,103939000.0,52767000.0,26242000.0,235913000.0,320357000.0,6390000.0,5944000.0,52767000.0,93622000.0,416981000.0,2111000.0,25100000.0,48868000.0,97400000.0,60878000.0,,,0.0,-16857000.0,-518000.0,-1550000.0,70324000.0,2363000.0,31519000.0,2324000.0,47559000.0,6101000.0,19000.0,-97006000.0,-13271000.0,-3395000.0,4937000.0,-16333000.0,,96624000.0,en-US,US,EQUITY,False,Delayed Quote,-10.391567,23.4555 - 24.8,26.56,finmb_4550716,Other OTC,Valneva SE,EUR,3203,15400,19.3,4.288889,4.5 - 28.25,-4.450001,-0.15752216,4.5,28.25,USD,PRE,23.8,1630526275,-2.7600002,24.56,24.8,23.4555,16052,us_market,2,0,0.7023085,VALNEVA SE,PNK,-1.306,0.567,14.846857,8.953142,0.6030328,13.981014,9.818985,2397612032,41.97531,15,America/New_York,EDT,-14400000,False,False,0.71,,,28.25,4.5,14.85,13.98,3.2k,15.4k,99.78M,,71.25M,15.59%,30.92%,,,,,,,,,,,0.00%,,,1108:1000,"Jan 14, 2015","Dec 30, 2020","Jun 29, 2021",-113.86%,-108.57%,-13.15%,-133.05%,109.92M,1.19,91.40%,-28.43M,-115.38M,-125.15M,-1.31,,329.77M,3.31,111.49M,144.65,1.23,0.57,108.77M,61.59M,Value,44800,Healthcare,700,10,10,"Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",Saint-Herblain,33 2 28 07 37 10,6,1609372800,1625097600,8,France,http://valneva.com,86400,10,6 rue Alain Bombard,Biotechnology
t-2,INRLF,43751000.0,99777600,,,-2040000,,-2059000,12842000,1733000,-1825000,-1825000,-9284000,-3688000,,,,19000,51473000,53298000,49740000,-215000,,-2059000,-2059000,33671000.0,244984000.0,371742000.0,77422000.0,116809000.0,449164000.0,13646000.0,57827000.0,-243023000.0,100105000.0,61815000.0,26783000.0,204435000.0,175870000.0,5570000.0,6988000.0,62713000.0,78153000.0,308427000.0,2130000.0,19232000.0,46375000.0,26933000.0,24898000.0,1738000.0,,54252000.0,-11268000.0,577000.0,-684000.0,33600000.0,2363000.0,48257000.0,103000.0,60107000.0,-821000.0,19000.0,800000.0,-36429000.0,-1252000.0,7278000.0,-11288000.0,-9000.0,132557000.0,en-US,US,EQUITY,False,Delayed Quote,-10.391567,23.4555 - 24.8,26.56,finmb_4550716,Other OTC,Valneva SE,EUR,3203,15400,19.3,4.288889,4.5 - 28.25,-4.450001,-0.15752216,4.5,28.25,USD,PRE,23.8,1630526275,-2.7600002,24.56,24.8,23.4555,16052,us_market,2,0,0.7023085,VALNEVA SE,PNK,-1.306,0.567,14.846857,8.953142,0.6030328,13.981014,9.818985,2397612032,41.97531,15,America/New_York,EDT,-14400000,False,False,0.71,,,28.25,4.5,14.85,13.98,3.2k,15.4k,99.78M,,71.25M,15.59%,30.92%,,,,,,,,,,,0.00%,,,1108:1000,"Jan 14, 2015","Dec 30, 2020","Jun 29, 2021",-113.86%,-108.57%,-13.15%,-133.05%,109.92M,1.19,91.40%,-28.43M,-115.38M,-125.15M,-1.31,,329.77M,3.31,111.49M,144.65,1.23,0.57,108.77M,61.59M,Value,44800,Healthcare,700,10,10,"Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",Saint-Herblain,33 2 28 07 37 10,6,1609372800,1625097600,8,France,http://valneva.com,86400,10,6 rue Alain Bombard,Biotechnology
t-3,INRLF,37172000.0,99777600,,,-35864000,,-36695000,12396000,-23888000,-31365000,-31365000,-3479000,-3592000,,,,831000,10941000,42306000,34829000,-4499000,,-36695000,-36695000,39556000.0,244946000.0,373457000.0,76728000.0,167073000.0,450185000.0,13643000.0,17348000.0,-188144000.0,70302000.0,6283000.0,24718000.0,156178000.0,201936000.0,5996000.0,7597000.0,7131000.0,71728000.0,311273000.0,2910000.0,109203000.0,46503000.0,28394000.0,13968000.0,,150000.0,39919000.0,-6241000.0,-587000.0,-2062000.0,11816000.0,192000.0,-43868000.0,-19000.0,-35588000.0,2447000.0,21000.0,1278000.0,-3406000.0,-1667000.0,-50947000.0,-5832000.0,-9000.0,109337000.0,en-US,US,EQUITY,False,Delayed Quote,-10.391567,23.4555 - 24.8,26.56,finmb_4550716,Other OTC,Valneva SE,EUR,3203,15400,19.3,4.288889,4.5 - 28.25,-4.450001,-0.15752216,4.5,28.25,USD,PRE,23.8,1630526275,-2.7600002,24.56,24.8,23.4555,16052,us_market,2,0,0.7023085,VALNEVA SE,PNK,-1.306,0.567,14.846857,8.953142,0.6030328,13.981014,9.818985,2397612032,41.97531,15,America/New_York,EDT,-14400000,False,False,0.71,,,28.25,4.5,14.85,13.98,3.2k,15.4k,99.78M,,71.25M,15.59%,30.92%,,,,,,,,,,,0.00%,,,1108:1000,"Jan 14, 2015","Dec 30, 2020","Jun 29, 2021",-113.86%,-108.57%,-13.15%,-133.05%,109.92M,1.19,91.40%,-28.43M,-115.38M,-125.15M,-1.31,,329.77M,3.31,111.49M,144.65,1.23,0.57,108.77M,61.59M,Value,44800,Healthcare,700,10,10,"Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.",Saint-Herblain,33 2 28 07 37 10,6,1609372800,1625097600,8,France,http://valneva.com,86400,10,6 rue Alain Bombard,Biotechnology
